Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancer PRINCETON, N.J., July 26, 2016 (GLOBE NEWSWIRE) -- Advaxis, …